{"title":"Lung function of tuberculosis patients after completion of treatment in Sidama, South Ethiopia.","authors":"Endrias Markos Woldesemayat, Jaime H Vera, Clea Tanner, Alemu Tamiso, Amare Assefa, Yohannes Markos Woldesenbet","doi":"10.3389/fmed.2025.1451861","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Lung function impairment are commonly reported after treatment of pulmonary tuberculosis (TB). This study aimed to examine lung function parameters among adults who have undergone treatment for pulmonary TB.</p><p><strong>Methods: </strong>A comparative cross-sectional study was conducted in eight rural communities of Dale district of Sidama Region, Southern Ethiopia. The post-TB group were smear-positive TB patients who successfully completed TB treatment between 2010 and 2021, while controls were selected from the neighbors of these participants with no documented history of TB. Lung function tests were conducted using a portable spirometer, and pulmonary symptoms were assessed using the Saint Georges Respiratory Questionnaire. Obstructive pulmonary impairment was defined as the ratio of FEV1/FVC below 70% and restrictive impairment was defined as having a normal FEV1/FVC ratio with a low FEV<sub>1</sub>. Data were entered and analyzed using SPSS version 25 statistical package.</p><p><strong>Results: </strong>We enrolled 167 TB cases and 156 controls in the study. The median (IQR) was 38 (21) years for cases and 35 (21.75) years for controls. The median (IQR) time after completion of TB treatment was 24 (31.75) months for the TB cases. A higher proportion of post-TB participants (101/167 (60.5%; 95% confidence interval (CI), 52.9-67.6%)) than controls (63/156 (40.4%; 95% CI, 33.0-48.2%)) had obstructive impairment, <i>p</i> = 0.01. Thirty eight (22.8; 95% CI, 17.1-29.7) post-TB participants and 39 (25.0%; 95% CI, 18.9-32.3%) controls had restrictive impairment; <i>p</i> = 0.3. Post-TB participants had high risk of obstructive pulmonary impairment (adjusted hazards ratio [aOR], 2.1; 95% CI, 1.3-3.3) and chronic obstructive pulmonary diseases symptoms scores (aOR, 73.0; 95% CI, 35.3-151.2). BMI was associated with obstructive impairment, (aOR, 1.6; 95% CI, 1.0-2.6) and the post-TB participants had increased risk of any impairment (aOR, 2.2; 95% CI, 1.1-4.5).</p><p><strong>Conclusion: </strong>Post-TB participants had greater risk of pulmonary impairment and respiratory symptoms. Post-TB treatment follow-up care is suggested to quickly identify and manage pulmonary impairment.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1451861"},"PeriodicalIF":3.1000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958218/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1451861","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Lung function impairment are commonly reported after treatment of pulmonary tuberculosis (TB). This study aimed to examine lung function parameters among adults who have undergone treatment for pulmonary TB.
Methods: A comparative cross-sectional study was conducted in eight rural communities of Dale district of Sidama Region, Southern Ethiopia. The post-TB group were smear-positive TB patients who successfully completed TB treatment between 2010 and 2021, while controls were selected from the neighbors of these participants with no documented history of TB. Lung function tests were conducted using a portable spirometer, and pulmonary symptoms were assessed using the Saint Georges Respiratory Questionnaire. Obstructive pulmonary impairment was defined as the ratio of FEV1/FVC below 70% and restrictive impairment was defined as having a normal FEV1/FVC ratio with a low FEV1. Data were entered and analyzed using SPSS version 25 statistical package.
Results: We enrolled 167 TB cases and 156 controls in the study. The median (IQR) was 38 (21) years for cases and 35 (21.75) years for controls. The median (IQR) time after completion of TB treatment was 24 (31.75) months for the TB cases. A higher proportion of post-TB participants (101/167 (60.5%; 95% confidence interval (CI), 52.9-67.6%)) than controls (63/156 (40.4%; 95% CI, 33.0-48.2%)) had obstructive impairment, p = 0.01. Thirty eight (22.8; 95% CI, 17.1-29.7) post-TB participants and 39 (25.0%; 95% CI, 18.9-32.3%) controls had restrictive impairment; p = 0.3. Post-TB participants had high risk of obstructive pulmonary impairment (adjusted hazards ratio [aOR], 2.1; 95% CI, 1.3-3.3) and chronic obstructive pulmonary diseases symptoms scores (aOR, 73.0; 95% CI, 35.3-151.2). BMI was associated with obstructive impairment, (aOR, 1.6; 95% CI, 1.0-2.6) and the post-TB participants had increased risk of any impairment (aOR, 2.2; 95% CI, 1.1-4.5).
Conclusion: Post-TB participants had greater risk of pulmonary impairment and respiratory symptoms. Post-TB treatment follow-up care is suggested to quickly identify and manage pulmonary impairment.
期刊介绍:
Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate
- the use of patient-reported outcomes under real world conditions
- the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines
- the scientific bases for guidelines and decisions from regulatory authorities
- access to medicinal products and medical devices worldwide
- addressing the grand health challenges around the world